Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    Pat Garcia-Gonzalez

    Executive Director, The Max Foundation


    Pat Garcia-Gonzalez, Executive Director of The Max Foundation, has been dedicated to improving the lives of blood cancer survivors around the world for over twelve years.  A native of Argentina, Pat has a Master degree from the University of Washington and technical degree in nursing. 


    Pat is co-founder of The Max Foundation, an international NGO based in Edmonds, Washington, started in 1997 to connect families facing leukemia with resources for treatment access. 


    Under Pat's direction since 2005, The Max Foundation provides services to over 15,000 CML patients in more than 90 countries annually and has successfully started and supported local patient organizations in 12 countries.


    In 2008, Pat was awarded the distinguished honor of the Golden Tennis Shoe Award from United States Senator, Patty Murray for her service and dedication to her community.   She is a member of the Global Health Council and of the CML Advocates Network.

    Francisco Cervantes

    Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic, in Barcelona, Spain, and associate professor at the University of Barcelona. His main scientific interest is the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published more than 190 articles in peer-review international journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology, Experimental Hematology, Haematologica, Cancer, Oncogene, Seminars in Oncology, and the European Journal of Haematology. In the CML field, Dr. Cervantes contributed to the elaboration of Sokal’s score, is a coauthor of the publications of the IRIS study, which established imatinib as first-line treatment for CML, has participated in the introduction of the second-generation tyrosine kinase inhibitors for patients resistant to imatinib, as well as in the authorship of the European LeukemiaNet recommendations for the treatment of CML. His more recent contributions in the field of the MPNs have been the elaboration of the new prognostic classification of primary myelofibrosis on behalf of the International Working Group for Myelofibrosis Research and Treatment, as well as several studies on the role of leukocyte and platelet activation in the thrombosis of MPN patients. At local level, he is the national coordinator of the CML studies within the collaborative PETHEMA Spanish group. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for Myeloproliferative Neoplasms Research and Treatment, the European Leukemianet, and the Spanish Society of Hematology.